#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14530	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2063	699.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1698	1698	T	826	T,C	752,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14530	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2063	699.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1432	1432	C	863	C	800	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14530	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2063	699.1	0	HET	.	.	.	C411T	.	411	411	C	659	659	C	883	C,T	624,183	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26552	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3476	761.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1613	1613	A	910	A,G	842,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26552	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3476	761.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2247	2247	C	845	C,T	764,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26552	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3476	761.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2321	2321	A	849	A	783	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26552	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3476	761.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2873	2873	C	816	C,A	763,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2146	folP	855	855	100.0	folP.l15.c4.ctg.1	1450	147.3	1	SNP	p	R229S	1	.	.	685	687	AGC	963	965	AGC	203;200;202	A;G;C	191;184;186	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5506	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3366	163.1	1	SNP	p	S91F	1	.	.	271	273	TTC	507	509	TTC	169;168;170	T;T;C	157;156;155	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5506	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3366	163.1	1	SNP	p	G95N	0	.	.	283	285	GGC	519	521	GGC	172;169;169	G;G;C,A	153;151;151,2	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5506	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3366	163.1	1	SNP	p	D95G	1	.	.	283	285	GGC	519	521	GGC	172;169;169	G;G;C,A	153;151;151,2	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1838	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1287	141.8	1	SNP	p	G45D	0	.	.	133	135	GGC	512	514	GGC	240;243;246	G;G;C	221;224;227	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	866	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	993	86.7	0	.	n	.	0	A197.	DEL	197	197	A	584	584	A	237	A	214	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5046	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2912	172.5	1	SNP	p	D86N	0	.	.	256	258	GAC	498	500	GAC	202;201;204	G,T;A;C	184,1;181;184	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5046	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2912	172.5	1	SNP	p	R87W	0	.	.	259	261	CGT	501	503	CGT	204;203;204	C;G;T	187;185;182	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5046	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2912	172.5	1	SNP	p	R87I	0	.	.	259	261	CGT	501	503	CGT	204;203;204	C;G;T	187;185;182	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5046	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2912	172.5	1	SNP	p	S87R	1	.	.	259	261	CGT	501	503	CGT	204;203;204	C;G;T	187;185;182	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5046	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2912	172.5	1	SNP	p	S88P	0	.	.	262	264	TCC	504	506	TCC	206;205;206	T;C;C	187;185;185	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4410	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2725	161.3	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1446	1448	TGC	188;188;188	T;G;C	174;177;180	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4410	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2725	161.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1656	1658	GGC	224;222;220	G;G;C	208;204;202	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1174	1176	GCA	245;244;241	G;C;A	221;220;222	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1177	1179	ATC	240;241;240	A;T;C	220;217;224	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1189	1191	GTG	233;232;234	G,C;T;G	216,1;213;216	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1189	1191	GTG	233;232;234	G,C;T;G	216,1;213;216	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1693	1695	ACC	215;211;211	A;C;C	193;195;195	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1747	1749	GCG	201;205;204	G;C;G	183;165;173	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1747	1749	GCG	201;205;204	G;C;G	183;165;173	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1870	1872	GGC	190;186;186	G;G;C	179;178;179	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1879	1881	GGC	182;181;179	G;G;C	174;169;169	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4114	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2377	172.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1897	1899	TCG	183;185;182	T,G;C;G,A	125,7;146;150,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5856	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3071	190.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1628	1630	CCG	198;200;201	C;C;G	176;187;177	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2262	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1647	136.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	499	499	C	139	C	131	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	V258L	NONSYN	772	774	GTA	100	102	TTA	55;55;55	T,G;T;A	47,1;48;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	145	147	CAT	70;69;67	C,T;A;T	58,1;57;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	D274S	NONSYN	820	822	GAT	148	150	AGT	66;65;65	A;G;T,G	57;56;56,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	157	159	TAC	67;67;66	T;A;C	59;59;59	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	R307A	NONSYN	919	921	AGA	247	249	GCA	18;19;20	G;C;A	18;19;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	T311A	NONSYN	931	933	ACA	259	261	GCA	18;20;20	G;C;A	18;20;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	E312V	NONSYN	934	936	GAA	262	264	GTC	20;20;20	G;T;C	20;20;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	F314I	NONSYN	940	942	TTC	268	270	ATC	21;21;20	A;T;C	20;20;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	A316S	NONSYN	946	948	GCG	274	276	TCG	19;19;18	T,G;C;G	18,1;18;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	V318A	NONSYN	952	954	GTC	280	282	GCC	19;19;21	G;C,T;C	14;18,1;19	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	G319S	NONSYN	955	957	GGC	283	285	AGC	21;22;22	A,G;G;C	18,1;21;20	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	G320A	NONSYN	958	960	GGT	286	288	GCC	22;22;22	G;C,G;C,T	20;20,1;20,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	354	porB1a	984	271	91.14	porB1a.l6.c30.ctg.2	388	33.7	0	.	p	.	0	G322V	NONSYN	964	966	GGT	292	294	GTT	23;23;23	G;T,G;T	22;22,1;22	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	434	436	GAA	219;219;216	G;A;A	204;204;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	N134D	NONSYN	400	402	AAT	722	724	GAT	241;239;242	G,A;A;T	227,1;223;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	845	847	TCA	261;261;264	T;C;A	237;239;243	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	D212N	NONSYN	634	636	GAT	956	958	AAT	197;200;201	A;A;T	188;193;189	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	F222L	NONSYN	664	666	TTT	986	988	CTT	212;210;210	C;T;T	198;196;196	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1304	1306	GCA	183;181;179	G;C;A	171;167;167	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1319	1321	GTC	180;179;182	G;T;C	171;167;170	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	1	SNP	p	G120K	1	.	.	358	360	AAG	680	682	AAG	237;239;238	A;A;G,C	222;221;220,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	1	SNP	p	D121N	0	.	.	361	363	GAC	683	685	GAC	235;235;235	G;A;C	219;217;220	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2694	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1511	177.4	1	SNP	p	A121D	1	.	.	361	363	GAC	683	685	GAC	235;235;235	G;A;C	219;217;220	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10550	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4957	212.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2003	2005	AAT	240;242;241	A;A;T	224;228;228	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1080	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1066	100.8	1	SNP	p	V57M	1	.	.	169	171	ATG	555	557	ATG	218;220;220	A;T;G	204;204;203	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
